Literature DB >> 10657011

Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease.

D F Dukers1, L H Jaspars, W Vos, J J Oudejans, D Hayes, S Cillessen, J M Middeldorp, C J Meijer.   

Abstract

Hodgkin's disease (HD) is a malignant lymphoproliferative disease characterized by the presence of Hodgkin-Reed-Sternberg cells surrounded by a reactive infiltrate. In Epstein-Barr virus (EBV)-associated cases (40-60%), at least two EBV-encoded proteins [latent membrane protein 1 (LMP1) and LMP2] are expressed, which are potential targets for cytotoxic T-lymphocytes (CTLs). Although in EBV-positive cases significantly more activated (granzyme B-positive) CTLs and natural killer (NK) cells are present, the cytotoxic immune response is not sufficient for adequate killing of tumour cells. The production of immunomodulating cytokines within the tumour may be one of the mechanisms causing circumvention of the immune system. This study investigated by immunohistochemistry the presence of the immunosuppressive cytokine interleukin-10 (IL-10) and other Th1/Th2-associated cytokines [IL-2, IL-4, interferon-gamma (IFN-gamma)] in the neoplastic cells and reactive lymphocytes of nine EBV-positive and 18 EBV-negative cases of HD. The percentage of IL-10-expressing cells, both neoplastic and reactive, in EBV-positive cases was significantly higher (33.1% vs. 18.5% for the neoplastic cells and 21.6% and 12.2% for the reactive cells, p=0.003 and 0.04, respectively) than in EBV-negative cases. No difference in the percentage of IL-2-, IL-4- and IFN-gamma-expressing cells was observed. These results suggest that escape from local immune surveillance is not due to a shift from Th1 towards Th2, but may be caused by a direct effect of IL-10 on the cytotoxic cells. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657011     DOI: 10.1002/(SICI)1096-9896(200002)190:2<143::AID-PATH519>3.0.CO;2-5

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  Hodgkin's disease and the Epstein-Barr virus.

Authors:  K J Flavell; P G Murray
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

4.  Molecular pathology of primary intraocular lymphoma.

Authors:  Chi-Chao Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2003

Review 5.  The role of T cells in the microenvironment of Hodgkin lymphoma.

Authors:  Frederik Wein; Ralf Küppers
Journal:  J Leukoc Biol       Date:  2015-08-28       Impact factor: 4.962

Review 6.  Immune escape of γ-herpesviruses from adaptive immunity.

Authors:  Zhuting Hu; Edward J Usherwood
Journal:  Rev Med Virol       Date:  2014-04-15       Impact factor: 6.989

7.  Interleukin-4 and interferon- γ levels in Epstein-Barr virus-associated infectious mononucleosis and nasopharyngeal carcinoma.

Authors:  Dyah R Budiani; Sofia M Haryana; Wihaskoro Sosroseno
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

8.  Gene Therapy for Pediatric Cancer: State of the Art and Future Perspectives.

Authors:  Ettore Biagi; Catherine Bollard; Raphael Rousseau; Malcolm Brenner
Journal:  J Biomed Biotechnol       Date:  2003

9.  Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.

Authors:  M Glavina-Durdov; J Jakic-Razumovic; V Capkun; P Murray
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

10.  PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma.

Authors:  Yuxuan Liu; Anke van den Berg; Rianne Veenstra; Bea Rutgers; Ilja Nolte; Gustaaf van Imhoff; Lydia Visser; Arjan Diepstra
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.